Biography
Specialties
Rehabilitation and Physical Medicine, Pain Management, Spinal Cord Injury Medicine
Rehabilitation and Physical Medicine, Pain Management, Spinal Cord Injury Medicine
Thomas N Bryce, MD
PROFESSOR | Rehabilitation and Human Performance
ASSOCIATE PROFESSOR | Neurosurgery
PROFESSOR | Rehabilitation and Human Performance
ASSOCIATE PROFESSOR | Neurosurgery
Are you a patient?
View my
Are you a patient?
View my
Biography
Specialties
Research
Dr. Bryce has been involved in several international taskforces related to outcome measures for pain after spinal cord injury, the International Dataset Project, and the classification of pain after spinal cord injury. The last of which he chaired.
At Mount Sinai, Dr. Bryce has been either the principal investigator or site principal investigator for the following funded studies:
A multi-center phase 2 trial eval-uating the efficacy and safety of our neural stem cells (HuCNS-SC) in patients with chronic cervical spinal cord injury
Evoked neuropathic pain in spinal cord injury
A phase II, multiple dose, double blinded, placebo controlled study of HP184 in chronic spinal cord injury patients
A multiple dose, double blinded, placebo controlled safety, tolerability and pharmacokinetic/ pharmacodynamic study of HP184 in chronic spinal cord injury patients
A multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the safety and efficacy of repeat treatment with two dose levels of BOTOX (r) (Botulinum Toxin Type A) purified neurotoxin complex followed by a treatment with BOTOX(r) in patients with urinary incontinence due to neurogenic detrusor overactivity
For a description of ongoing research projects go to this link:
http://labs.icahn.mssm.edu/brycelab/
At Mount Sinai, Dr. Bryce has been either the principal investigator or site principal investigator for the following funded studies:
A multi-center phase 2 trial eval-uating the efficacy and safety of our neural stem cells (HuCNS-SC) in patients with chronic cervical spinal cord injury
Evoked neuropathic pain in spinal cord injury
A phase II, multiple dose, double blinded, placebo controlled study of HP184 in chronic spinal cord injury patients
A multiple dose, double blinded, placebo controlled safety, tolerability and pharmacokinetic/ pharmacodynamic study of HP184 in chronic spinal cord injury patients
A multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the safety and efficacy of repeat treatment with two dose levels of BOTOX (r) (Botulinum Toxin Type A) purified neurotoxin complex followed by a treatment with BOTOX(r) in patients with urinary incontinence due to neurogenic detrusor overactivity
For a description of ongoing research projects go to this link:
http://labs.icahn.mssm.edu/brycelab/
Education
MD, Albany Medical College
Internship, Internal Medicine, Albany Medical Center
Residency, Physical Medicine & Rehabilitation, Thomas Jefferson University Hospital
Certifications
American Board of Physical Medicine and Rehab
Office Locations
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. Bryce did not report having any of the following types of financial relationships with industry and other outside entities during 2023 and/or 2024: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. Bryce did not report having any of the following types of financial relationships with industry and other outside entities during 2023 and/or 2024: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.